300 related articles for article (PubMed ID: 28250127)
1. Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP Administered Intranasally Is Immunogenic in African Green Monkeys.
Lingemann M; Liu X; Surman S; Liang B; Herbert R; Hackenberg AD; Buchholz UJ; Collins PL; Munir S
J Virol; 2017 May; 91(10):. PubMed ID: 28250127
[TBL] [Abstract][Full Text] [Related]
2. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
[TBL] [Abstract][Full Text] [Related]
3. Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response.
DiNapoli JM; Yang L; Samal SK; Murphy BR; Collins PL; Bukreyev A
Vaccine; 2010 Dec; 29(1):17-25. PubMed ID: 21034822
[TBL] [Abstract][Full Text] [Related]
4. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.
Mackow N; Amaro-Carambot E; Liang B; Surman S; Lingemann M; Yang L; Collins PL; Munir S
J Virol; 2015 Oct; 89(20):10319-32. PubMed ID: 26223633
[TBL] [Abstract][Full Text] [Related]
5. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
[No Abstract] [Full Text] [Related]
6. Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic.
Bukreyev AA; Dinapoli JM; Yang L; Murphy BR; Collins PL
Virology; 2010 Apr; 399(2):290-8. PubMed ID: 20129638
[TBL] [Abstract][Full Text] [Related]
7. A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals.
Yang L; Sanchez A; Ward JM; Murphy BR; Collins PL; Bukreyev A
Virology; 2008 Aug; 377(2):255-64. PubMed ID: 18570964
[TBL] [Abstract][Full Text] [Related]
8. Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.
Konduru K; Shurtleff AC; Bradfute SB; Nakamura S; Bavari S; Kaplan G
PLoS One; 2016; 11(9):e0162446. PubMed ID: 27622456
[TBL] [Abstract][Full Text] [Related]
9. Genetically modified rabies virus-vectored Ebola virus disease vaccines are safe and induce efficacious immune responses in mice and dogs.
Shuai L; Wang X; Wen Z; Ge J; Wang J; Zhao D; Bu Z
Antiviral Res; 2017 Oct; 146():36-44. PubMed ID: 28822816
[TBL] [Abstract][Full Text] [Related]
10. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.
Schweneker M; Laimbacher AS; Zimmer G; Wagner S; Schraner EM; Wolferstätter M; Klingenberg M; Dirmeier U; Steigerwald R; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331098
[TBL] [Abstract][Full Text] [Related]
11. A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques.
Singh K; Marasini B; Chen X; Ding L; Wang JJ; Xiao P; Villinger F; Spearman P
J Virol; 2020 Apr; 94(9):. PubMed ID: 32075939
[TBL] [Abstract][Full Text] [Related]
12. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.
Kimble JB; Malherbe DC; Meyer M; Gunn BM; Karim MM; Ilinykh PA; Iampietro M; Mohamed KS; Negi S; Gilchuk P; Huang K; Wolf YI; Braun W; Crowe JE; Alter G; Bukreyev A
J Virol; 2019 Feb; 93(4):. PubMed ID: 30518655
[TBL] [Abstract][Full Text] [Related]
13. Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge.
Bukreyev A; Marzi A; Feldmann F; Zhang L; Yang L; Ward JM; Dorward DW; Pickles RJ; Murphy BR; Feldmann H; Collins PL
Virology; 2009 Jan; 383(2):348-61. PubMed ID: 19010509
[TBL] [Abstract][Full Text] [Related]
14. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of propagation-restricted vesicular stomatitis virus encoding Ebola virus glycoprotein in guinea pigs.
Locher S; Schweneker M; Hausmann J; Zimmer G
J Gen Virol; 2018 Jul; 99(7):866-879. PubMed ID: 29869979
[TBL] [Abstract][Full Text] [Related]
16. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
[TBL] [Abstract][Full Text] [Related]
17. Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes.
Bartlett EJ; Castaño A; Surman SR; Collins PL; Skiadopoulos MH; Murphy BR
Virol J; 2007 Jul; 4():67. PubMed ID: 17605811
[TBL] [Abstract][Full Text] [Related]
18. Intranasal immunization with recombinant Vaccinia virus Tiantan harboring Zaire Ebola virus gp elicited systemic and mucosal neutralizing antibody in mice.
Xie L; Zai J; Yi K; Li Y
Vaccine; 2019 May; 37(25):3335-3342. PubMed ID: 31076161
[TBL] [Abstract][Full Text] [Related]
19. Construction and evaluation of DNA vaccine encoding Ebola virus glycoprotein fused with lysosome-associated membrane protein.
Liu Y; Sun B; Pan J; Feng Y; Ye W; Xu J; Lan M; Sun H; Zhang X; Sun Y; Yang S; Shi J; Zhang F; Cheng L; Jiang D; Yang K
Antiviral Res; 2021 Sep; 193():105141. PubMed ID: 34274417
[TBL] [Abstract][Full Text] [Related]
20. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.
Ledgerwood JE; Costner P; Desai N; Holman L; Enama ME; Yamshchikov G; Mulangu S; Hu Z; Andrews CA; Sheets RA; Koup RA; Roederer M; Bailer R; Mascola JR; Pau MG; Sullivan NJ; Goudsmit J; Nabel GJ; Graham BS;
Vaccine; 2010 Dec; 29(2):304-13. PubMed ID: 21034824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
